Towards Selective Kinase Inhibitors by Chemical Genetics and Photopharmacology

Autor: Aguirre, Tim

In dieser Arbeit wurden verschiedene Ansätze verfolgt, um selektive Kinaseinhibitoren für verschiedene Ziele zu entwickeln. Ein chemisch-genetisches Verfahren, das als "analog-sensitiv" bezeichnet wird, wurde eingesetzt, um isozymselektive Inhibito

Externí odkaz: http://edoc.hu-berlin.de/18452/28294

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Inhibiting IP6K1 confers atheroprotection by elevating circulating apolipoprotein A-I.

Autor: Liu X; Tianjin Key Laboratory of Metabolic Diseases, Department of Physiology and Pathophysiology, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, 22 Qixiangtai Road, Tianjin 300070, China., Zhang Z; Tianjin Key Laboratory of Metabolic Diseases, Department of Physiology and Pathophysiology, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, 22 Qixiangtai Road, Tianjin 300070, China., Aguirre T; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin 13125, Germany., Shipton ML; Medicinal Chemistry & Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK., Fu L; Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China., Du J; Tianjin Key Laboratory of Metabolic Diseases, Department of Physiology and Pathophysiology, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, 22 Qixiangtai Road, Tianjin 300070, China., Furkert D; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin 13125, Germany., Qi J; Institute for Developmental and Regenerative Cardiovascular Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China., Chin AC; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY 10065, USA., Riley AM; Medicinal Chemistry & Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK., Liu T; Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China., Zhang X; Tianjin Key Laboratory of Metabolic Diseases, Department of Physiology and Pathophysiology, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, 22 Qixiangtai Road, Tianjin 300070, China., Potter BVL; Medicinal Chemistry & Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK., Fiedler D; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin 13125, Germany., Zhu Y; Tianjin Key Laboratory of Metabolic Diseases, Department of Physiology and Pathophysiology, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, 22 Qixiangtai Road, Tianjin 300070, China. Electronic address: zhuyi@tmu.edu.cn., Fu C; Tianjin Key Laboratory of Metabolic Diseases, Department of Physiology and Pathophysiology, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, 22 Qixiangtai Road, Tianjin 300070, China; Institute for Developmental and Regenerative Cardiovascular Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China. Electronic address: fuchenglai@xinhuamed.com.cn.

Publikováno v: Metabolism: clinical and experimental [Metabolism] 2024 Dec 04; Vol. 163, pp. 156098. Date of Electronic Publication: 2024 Dec 04.